New Delhi, May 21 (IANS) A team of scientists at the Institute of Advanced Study in Science and Technology (IASST), an autonomous institute of the Department of Science and Technology (DST), has found drugs with potential to treat neurodegenerative disorders — a major global health challenge.
In the study, published in the Journal Drug Discovery Today, the team highlighted the potential of peptidomimetics to treat neurodegenerative diseases, like Alzheimer’s disease, Parkinson’s disease, by promoting neuronal growth and survival.
Peptidomimetic drugs — or synthetic molecules that mimic the structure of natural proteins — can be repurposed to provide an effective therapeutic strategy to treat neurodegenerative diseases by promoting neuronal growth and survival.
While neurotrophins, proteins crucial for neuronal survival and function, have shown promise as potential treatments, their instability and rapid degradation have hindered their therapeutic application.
IASST scientists have been exploring peptidomimetics, synthetic compounds designed to mimic neurotrophins, as a potential solution to these limitations.
“Neurotrophin peptidomimetics are developed to target specific biological functions and can be valuable tools in drug discovery, especially when natural peptides have limitations like poor oral bioavailability or susceptibility to degradation,” said the team led by Prof. Ashis K. Mukherjee.
“One of the significant advantages of peptidomimetics is their improved stability and bioavailability compared to endogenous neurotrophins. This means they can be delivered more effectively to the brain and maintain their therapeutic activity for a longer duration,” the team added.
In addition, peptidomimetics can be designed to be more specific to their target receptors, reducing the risk of side effects.
The research focused on understanding the signaling pathways involved in neuronal growth and survival, the potential pharmacological targets of peptidomimetics, and their therapeutic applications for neurodegenerative diseases.
The team also explored the possibility of repurposing existing peptidomimetic drugs for other diseases, such as cancer, and the potential for developing new drug prototypes based on neurotrophins mimetics.
As research progresses, the team said that peptidomimetics could become a key therapeutic strategy, offering new hope for managing and treating neurodegenerative disorders for future generations.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
